Parkinson disease-associated cognitive impairment

D Aarsland, L Batzu, GM Halliday… - Nature reviews Disease …, 2021 - nature.com
Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

The genetic architecture of Parkinson's disease

C Blauwendraat, MA Nalls, AB Singleton - The Lancet Neurology, 2020 - thelancet.com
Parkinson's disease is a complex neurodegenerative disorder for which both rare and
common genetic variants contribute to disease risk, onset, and progression. Mutations in …

[КНИГА][B] ACSM's guidelines for exercise testing and prescription

G Liguori, American College of Sports Medicine - 2020 - books.google.com
The flagship title from the prestigious American College of Sports Medicine, this critical
handbook delivers scientifically based, evidence-informed standards to prepare you for …

[HTML][HTML] Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

ER Dorsey, A Elbaz, E Nichols, N Abbasi… - The Lancet …, 2018 - thelancet.com
Background Neurological disorders are now the leading source of disability globally, and
ageing is increasing the burden of neurodegenerative disorders, including Parkinson's …

A statement of the MDS on biological definition, staging, and classification of Parkinson's disease

F Cardoso, CG Goetz, TA Mestre… - Movement …, 2024 - Wiley Online Library
Disease staging is an important tool in both clinical research and medical practice because
it allows for an unequivocal allocation of individuals into groups of shared biomedical …

Parkinson's disease: Mechanisms, translational models and management strategies

C Raza, R Anjum - Life sciences, 2019 - Elsevier
Parkinson's disease is a progressive neurodegenerative disorder. The classical motor
symptoms include resting tremors, bradykinesia, rigidity and postural instability and are …

Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies

CH Gibbons, T Levine, C Adler, B Bellaire, N Wang… - Jama, 2024 - jamanetwork.com
Importance Finding a reliable diagnostic biomarker for the disorders collectively known as
synucleinopathies (Parkinson disease [PD], dementia with Lewy bodies [DLB], multiple …

Towards fog-driven IoT eHealth: Promises and challenges of IoT in medicine and healthcare

B Farahani, F Firouzi, V Chang, M Badaroglu… - Future generation …, 2018 - Elsevier
Abstract Internet of Things (IoT) offers a seamless platform to connect people and objects to
one another for enriching and making our lives easier. This vision carries us from compute …

Virtual reality rehabilitation versus conventional physical therapy for improving balance and gait in Parkinson's disease patients: a randomized controlled trial

H Feng, C Li, J Liu, L Wang, J Ma, G Li… - … medical journal of …, 2019 - pmc.ncbi.nlm.nih.gov
Background The aim of this study was to investigate the effect of virtual reality (VR)
technology on balance and gait in patients with Parkinson's disease (PD). Material/Methods …

Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments

P Maiti, J Manna, GL Dunbar - Translational neurodegeneration, 2017 - Springer
Gradual degeneration and loss of dopaminergic neurons in the substantia nigra, pars
compacta and subsequent reduction of dopamine levels in striatum are associated with …